Item 7.01 Regulation FD Disclosure.

On January 26, 2023, Ventyx Biosciences, Inc. ("Ventyx") hosted an Investor R&D Day highlighting key aspects of its clinical-stage and discovery programs. During the webcast, Ventyx presented the slides attached as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated herein solely for purposes of this Item 7.01 disclosure.

Also on January 26, 2023, Ventyx issued a press release announcing the pipeline updates and strategic priorities presented at the Investor R&D Day. The press release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein solely for purposes of this Item 7.01 disclosure.

In accordance with General Instruction B.2. of Form 8-K, all of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.       Description

99.1          Corporate Presentation - January 26, 2023

99.2          Press Release, dated January 26, 2023

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses